A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer

Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter. Over all response was 36% with 9% complete responses. The most common grade 3 and 4 toxicities were stomatitis (13), infection (5), pain related to vinorel...

Full description

Saved in:
Bibliographic Details
Published inActa oncologica Vol. 46; no. 3; pp. 374 - 377
Main Authors Larsen, Susanne, Serup-Hansen, Eva, Andersen, Lisbeth J., Lindeløv, Birgit, McCulloch, Tine, Adimi, Parvin, Bastholt, Lars
Format Journal Article
LanguageEnglish
Published England Informa UK Ltd 2007
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Catheterization, Central Venous - adverse effects
Disease Progression
Dose-Response Relationship, Drug
Feasibility Studies
Female
Fluorouracil - administration & dosage
Follow-Up Studies
Head and Neck Neoplasms - drug therapy
Humans
Infection - etiology
Infusions, Intravenous
Leukopenia - chemically induced
Male
Middle Aged
Pain - chemically induced
Skin Diseases - chemically induced
Stomatitis - chemically induced
Survival Analysis
Treatment Outcome
Vinblastine - administration & dosage
Vinblastine - analogs & derivatives
Online AccessGet full text

Cover

More Information
Summary:Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter. Over all response was 36% with 9% complete responses. The most common grade 3 and 4 toxicities were stomatitis (13), infection (5), pain related to vinorelbine infusion (4), skin toxicity (3). Thirty one patients had grade 3 or 4 leukopenia. Treatment was complicated by venous thrombosis in the central venous catheter in one case. A majority of patients experienced dose reduction of one or both drugs or treatment delays due to toxicity. Median time to progression was 4.7 months and overall median survival 6.6 months. We conclude that the regimen is feasible and tolerated with moderate toxicity. Response rates and time to progression are comparable to other studies with multi agent treatment.
ISSN:0284-186X
1651-226X
DOI:10.1080/02841860600959981